



PTO/SB/08A (03-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PT

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

How many sheets of paper?

Sheet 1 of 3

三

Application Number	10/081,713
Filing Date	February 21, 2002
First Named Inventor	C. PLATA-SALAMAN et al.
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	ORT-1583

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature	Phillis Spivack	Date Considered	9/10/03
-----------------------	-----------------	--------------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance
and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED
JUN 02 2003
TECH CENTER 1800/2900



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 3

Application Number	10/081,713
Filing Date	February 21, 2002
First Named Inventor	C. PLATA-SALAMAN et al
Group Art Unit	1614
Examiner Name	William Jarvis
Attorney Docket Number	ORT-1583

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (In CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
DS	/	STEIN, M.B., Neurobiological Perspectives on Social Phobia: From Affiliation to Zoology, Biol. Psychiatry, 1998, 44 (12), 1277-1285.	
IPB	/	NEWBURN, G., Psychiatric Disorders Associated with Traumatic Brain Injury, Optimal Treatment, CNS Drugs, 1998, 9 (6), 441-456.	
PS	/	LIDBERG, L., et al., Suicide Attempts and Impulse Control Disorder are Related to Low Cerebrospinal Fluid 5-HIAA in Mentally Disordered Violent Offenders, Acta Psychiatr. Scand., 2000, 101 (5), 395-402.	
PS	/	VAN AMERingen, M., et al., Drugs In Development for Social Anxiety Disorder: More to Social Anxiety Than Meets the SSRI, expert Opin. Invest. Drugs, 2000, 9 (10), 2215-2231.	
PS	/	ZHUANG, S., et al., Altered Emotional States in Knockout Mice Lacking 5-HT1A or 5-HT1B Receptors, Neuropsychopharmacology, 1999, 21 (2S), 52S-60S.	
PS	/	MIVATA, Y., et al., Carbamazepine Augmentation of Clomipramine in the Treatment of Refractory Obsessive-Compulsive Disorder [letter], J. Clinical Psychiatry, 2000, 61 (7), 528-529.	
PS	/	HOLLANDER, E., Managing Aggressive Behavior in Patients with Obsessive-Compulsive Disorder and Borderline Personality Disorder, J. Clinical Psychiatry, 1999, 60 (Suppl), 1538-1544.	
PS	/	CORA-LOCATELLI, G., et al., Gabapentin Augmentation for Fluoxetine-Treated Patients with Obsessive-Compulsive Disorder [letter], J. Clinical Psychiatry, 1998, 59 (9), 480-481.	
PS	/	KOOPONWITZ, L.E., et al., Response of Obsessive Compulsive Disorder to Carbamazepine in Two Patients with Comorbid Epilepsy, Annals of Clinical Psychiatry, 1997, 9 (3), 171-173.	
PS	/	JEFFERSON, J.W., Benzodiazepines and Anticonvulsants for Social Phobia (Social Anxiety Disorder), J. Clin. Psychiatry, 2001, 62 (Suppl. 1), 50-53.	
IPB	/	CONNOR, K.M., et al., Social Phobia: Issues In Assessment and Management, Epilepsia, 1999, 40 (Suppl 6), S60-65.	
DS	/	BRODSKY, L., et al., Post Traumatic Stress Disorder: An Eclectic Approach, International Journal of Psychosomatics, 1990, 37 (1-4), 89-95.	
PS	/	ADAMEC, R., et al., Effects of Baseline Anxiety on Response to Kindling of the Right Medial Amygdala, Physiol Behav., 2000, 70 (1/2), 67-80.	
RECEIVED	/	FRIEDMAN, M.J., What Might the Psychobiology of Posttraumatic Stress Disorder Teach Us About Future Approaches to Pharmacotherapy?, J. clin. Psychiatry, 2000, 61 (Suppl. 7), 44-51.	
IPB	/	STAM, R., et al., Long-lasting Stress Sensitization, Eur. J. Pharmacol., 2000, 405 (1-3), 217-224.	
IPB	/	SOUTHWICK, S.M., et al., Role of Norepinephrine in the Pathophysiology and Treatment of Posttraumatic Stress Disorder, Biol. Psychiatry, 1999, 46 (8), 1192-1204.	
IPB	/	HERTZBERG, M.A., et al., A Preliminary Study of Lamotrigine for theTreatment of Posttraumatic Stress Disorder, Biol. Psychiatry, 1999, 45, 1226-1229.	
IPB	/	DAVIDSON, J., Biological Therapies for Posttraumatic Stress Disorder: An Overview, J. Clinical Psychiatry, 1997, 58 (Suppl), 29-32.	
IPB	/	FRIEDMAN, M.J., Drug Treatment for PTSD, Answers and Questions, Annals of the New York Academy of Sciences, 1997 (JUN 21), 821, 359-371.	
IPB	/	FORD, N., The Use of Anticonvulsants in Posttraumatic Stress Disorder: Case Study and Overview, J. Traumatic Stress, 1996, 9 (4), 857-863.	
PS	/	SUTHERLAND, S.M., et al., Pharmacotherapy for Post-Traumatic Stress Disorder, Psychiatric Clinics of North America, 1994, 17 (2), 409-423.	
PS	/	KECK, P.E., et al., Valproate and Carbamazepine in the Treatment of Panic and Posttraumatic Stress Disorders, Withdrawal States, and Behavioral Dyscontrol Syndromes, J. OF CLINICAL Psychopharmacology, 1992, 12 (1 Suppl), 36S-41S.	
PS	/	BERIGAN, T., et al., Valproate as an Alternative in Post-Traumatic Stress Disorder: A Case Report, Military Medicine, 1995, 160 (6) 318 .	
PS	/	BERLANT, J., Topiramate in Chronic Civilian Posttraumatic Stress Disorder - An Open Label Study of a Novel Treatment, International Society for Traumatic Stress Studies, Melbourne, Australia, 2000 .	
PS	/	BRANNON, N., et al., Gabapentin Treatment for Posttraumatic Stress Disorder, Canadian J. Psychiatry, 2000, 45 (1) 84 .	
IPB	/	CLARK, R.D., et al., Divalproex in Posttraumatic Stress Disorder: An Open-Label Clinical Trial, J. Trauma. Stress, 1999, 12 (2) 395-401 .	
PS	/	FESLER, F.A., Valproate in Combat-Related Posttraumatic Stress Disorder, J. Clin. Psychiatry, 1991, 52 (9) 361-364.	

Examiner Signature	<i>William Jarvis</i>	Date Considered	9/10/03
--------------------	-----------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

TECH CENTER 1600/2000



Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it displays a valid OMB control number.

Approved for use through 10/31/2002. OMB 0551-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
in a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 3

Application Number	10/081,713
Filing Date	February 21, 2002
First Named Inventor	C. PLATA-SALAMAN et al.
Group Art Unit	1614
Examiner Name	William Jarvis
Attorney Docket Number	ORT-1583

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Signature Fluffia Spivack **Date Considered** 9/10/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

• 1 Unique citation designation number. • 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.



SUBMISSION UNDER MPEP 609 D	Application Number 10/081,713 Filing Date February 21, 2002 First Named Inventor C. PLATA-SALAMAN et al. Group Art Unit 1614 Examiner Name William Jarvis Attorney Docket Number ORT-1583
Page 1 of 1	

SUBMISSION UNDER MPEP 609 D


Page 1 of 1

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



JUN 09 2003

JUN 11 2003

TECH CENTER 1600/2900

PTO/SB/08A (03-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

6.00 am to 6.00 pm daily in an accessible area.

Sheet 1 of 2

Application Number	10/081,713
Filing Date	February 21, 2002
First Named Inventor	C. Plata-Salaman
Group Art Unit	1614
Examiner Name	SPIVACK
Attorney Docket Number	ORT-1583

U.S. PATENT DOCUMENTS

REVOLVED

FOREIGN PATENT DOCUMENTS

**Examiner
Signature**

~~This is Sewack~~

Date Considered

9/10/03

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance
not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

JUN 11 2003

TECH CENTER 1600/2900

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE



JUN 09 2003

I understand the Paperwork Reduction Act of 1995, no persons are required to respond

Form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Application Number	10/081,713
Filing Date	February 21, 2002
First Named Inventor	C. Plata-Salaman
Group Art Unit	1614
Examiner Name	W. Jarvis
Attorney Docket Number	ORT-1583

OTHER PRICES ART: NON-PATENT LITERATURE DOCUMENTS

**Examiner
Signature**

Phyllis Spiack

Date Considered:


9 photos

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in accordance with MPEP 609. Indicate reason for non-compliance. Include copy of this form with next communication to applicant.

Unique citation designation number. Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments or the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



JUN 09 2003

SUBMISSION UNDER MPEP 609 D

Page 1 of 1

Application Number	10/081,713
Filing Date	February 21, 2002
First Named Inventor	C. Plata-Salaman
Group Art Unit	1614
Examiner Name	W. Jarvis
Attorney Docket Number	ORT-1583

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Name of Patentee or Applicant of Cited Document	U.S. Patent Document		Pages, Columns, Lines, where relevant passages or relevant figures appear
			Number	Kind Code ² (if known)	
		Ortho-McNeil Pharmaceutical, Inc.	USSN 09/906,254 our docket no. ORT-1463		
		Ortho-McNeil Pharmaceutical, Inc.	USSN 10/084,581 our docket no. ORT-1577		
		Ortho-McNeil Pharmaceutical, Inc.	USSN 10/081,600 our docket no. ORT-1581		
		Ortho-McNeil Pharmaceutical, Inc.	USSN 10/192,873 our docket no. ORT-1642		
		Ortho-McNeil Pharmaceutical, Inc.	USSN 10/081,943 our docket no. ORT-1578		
		Ortho-McNeil Pharmaceutical, Inc.	USSN 10/193,600 our docket no. ORT-1641		
		Ortho-McNeil Pharmaceutical, Inc.	USSN 10/081,764 our docket no. ORT-1575		

TECH CENTER 1600/2900

TECH CENTER 1600/2900

JUL 25 2003

RECEIVED

Examiner Signature	Date Considered	
-----------------------	--------------------	--